Shanghai Yizhong Pharmaceutical Co., Ltd.

- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-09-10
- Employees
- 304
- Market Cap
- -
- Website
- http://www.yizhongpharma.com
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer Metastatic
- Interventions
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
- Target Recruit Count
- 416
- Registration Number
- NCT06752811
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer (MBC)
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06143553
- Locations
- 🇨🇳
Jiangsu province Hospital, Nanjing, Jiangsu, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC
- Conditions
- Non-Small Cell Lung Cancer(NSCLC)
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
- Target Recruit Count
- 454
- Registration Number
- NCT02667743
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, Zhejiang, China